Q2 Earnings Forecast for VRDN Issued By B. Riley

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Analysts at B. Riley issued their Q2 2025 earnings estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($1.14) for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.05 million.

Several other research firms have also recently issued reports on VRDN. TD Cowen assumed coverage on shares of Viridian Therapeutics in a research report on Monday, November 25th. They set a “buy” rating on the stock. Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 price objective (down previously from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Royal Bank of Canada raised their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Viridian Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $35.70.

Viridian Therapeutics Trading Down 7.2 %

Viridian Therapeutics stock opened at $14.41 on Tuesday. The stock has a market cap of $1.14 billion, a P/E ratio of -3.34 and a beta of 1.32. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The firm’s 50 day moving average price is $18.10 and its 200-day moving average price is $19.70.

Institutional Trading of Viridian Therapeutics

A number of large investors have recently made changes to their positions in the stock. FMR LLC boosted its stake in shares of Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company’s stock valued at $227,776,000 after purchasing an additional 698,434 shares during the period. Vanguard Group Inc. boosted its stake in shares of Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company’s stock valued at $88,087,000 after purchasing an additional 174,952 shares during the period. Deep Track Capital LP boosted its stake in shares of Viridian Therapeutics by 20.6% during the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company’s stock valued at $86,701,000 after purchasing an additional 771,796 shares during the period. Tang Capital Management LLC boosted its stake in shares of Viridian Therapeutics by 11.1% during the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock valued at $47,789,000 after purchasing an additional 250,000 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Viridian Therapeutics by 3.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company’s stock valued at $43,842,000 after purchasing an additional 84,255 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.